Phase I study pilot arms of radiotherapy and carmustine with temozolomide for anaplastic astrocytoma (Radiation Therapy Oncology Group 9813): implications for studies testing initial treatment of brain tumors

International Journal of Radiation Oncology, Biology, Physics
Susan M ChangMinesh Mehta

Abstract

To determine the safety and toxicity of carmustine (BCNU) and temozolomide (TMZ) with radiotherapy (RT) in newly diagnosed anaplastic astrocytoma. Patients >18 years old with anaplastic astrocytoma, a Karnofsky performance status score of > or =60, and adequate pulmonary function were eligible. All patients provided informed consent. Standard RT started within 5 weeks of diagnosis. In both arms, 150 mg/m(2) of TMZ was given on Days 1-5 of RT. In Arm 1, 200 mg/m(2) of carmustine was given on Day 1 of RT. In Arm 2, 150 mg/m(2) of carmustine was given on Day 5 of RT. After RT, TMZ and carmustine were repeated for a total of six cycles. A total of 15 and 14 patients were enrolled in the two pilot arms. Because of hematologic and pulmonary toxicities, dose reductions by the second cycle of therapy occurred in >70% of the patients in Arm 1 and >50% in Arm 2 despite a reduction in the carmustine dose. The results of these pilot studies have implications for the design of studies testing the initial treatment of brain tumors. Because of the poor tolerance of the combination, the multicooperative group Phase III study consists of two randomized arms of single-agent carmustine vs. single-agent TMZ.

References

Dec 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E S NewlandsP G Richards
Jan 1, 1997·Cancer Chemotherapy and Pharmacology·M BowerM H Brampton
Apr 18, 2001·Controlled Clinical Trials·D J SargentR M Goldberg
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer A QuinnHenry S Friedman

❮ Previous
Next ❯

Citations

Sep 15, 2009·Medical Physics·Xiaodong ZhongJing Cai
Jun 7, 2007·Mayo Clinic Proceedings·Fabien MaldonadoMarie-Christine Aubrey
Oct 1, 2010·Medical Physics·Stanley H BenedictFang-Fang Yin
Sep 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer A QuinnHenry S Friedman
Apr 18, 2008·Expert Review of Neurotherapeutics·Marc C ChamberlainMichael J Glantz
Sep 18, 2012·Radiation Oncology Journal·Yunseon ChoiJinsil Seong
Jun 28, 2012·Journal of Korean Neurosurgical Society·Sung Kwon KimChul-Kee Park
Jan 28, 2005·Journal of Neuro-oncology·Joachim M Baehring

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

© 2022 Meta ULC. All rights reserved